We previously reported that acute inhibition of the RhoA/Rho kinase (ROCK) pathway 29 normalized contractile function of diabetic rat hearts, but the underlying mechanism is unclear. 30 PKCβ 2 has been proposed to play a major role in diabetic cardiomyopathy at least in part by 31 increasing oxidative stress. Further evidence suggests that PKC positively regulates RhoA 32 expression through induction of iNOS in diabetes. However, in preliminary studies we found that 33 inhibition of ROCK itself reduced RhoA expression in diabetic hearts. We hypothesized that 34 there is an interaction between RhoA/ROCK and PKCβ 2 in the form of a positive feedback loop 35 that sustains their activation and the production of reactive oxygen species (ROS). This was 36 investigated in cardiomyocytes isolated from diabetic and control rat hearts, incubated with or 37 without cytochalasin D or inhibitors of ROCK, RhoA, PKCβ 2 or iNOS. Inhibition of RhoA and 38
Introduction 51
Diabetic cardiomyopathy, characterized by early diastolic and later systolic dysfunction 52 independent of hypertension or coronary artery disease, is a common complication of diabetes 53 mellitus (3, 51) that contributes to the development of heart failure, one of the most common 54 causes of morbidity and mortality in this condition (3). Presently, there is no specific drug 55 available for its prevention or treatment. 56
The RhoA/Rho-kinase (ROCK) pathway regulates several vital cellular processes including cell 57 growth, morphology, contraction and gene transcription. Elevated activity of this pathway has 58 been implicated in a number of cardiovascular diseases including cerebral stroke (50), 59
hypertension (10), heart failure (29) and atherosclerosis (36). We have also shown that the 60
RhoA/ROCK pathway is also implicated in diabetic cardiomyopathy and that acute inhibition of 61 ROCK improved contractile function of hearts from type 1 diabetic rats both in vitro and in vivo 62 (32) . Recently it was shown that chronic treatment with the ROCK inhibitor fasudil prevented 63 the development of cardiac contractile dysfunction in a model of type 2 diabetes (62). However 64 ATP, 0.1% β-mercaptoethanol and 500 ng truncated MYPT1 , and incubated at 30°C for 166 30 minutes. The level of Thr696 phosphorylation of MYPT1 was determined by Western 167 blotting. 168
169

Western Blot 170
Proteins from each sample were separated by 8-12% SDS-PAGE and immunoblotted using 171 primary antibodies against iNOS, GAPDH , CMV promoter at a multiplicity of infection (MOI) of 400 (Applied Biological Materials Inc., 186 Canada), for 90 minutes. Afterwards, the medium was changed to medium 199 containing either 187 5.5mM or 25mM glucose and cells were incubated for 24 hours.
Determination of ROS levels 189
The levels of ROS were measured using live cell imaging of dihydroethidium (DHE)-loaded 190 cardiomyocytes. After treatment for the specified periods, cells were incubated in Hank's 191 balanced salt solution containing 5 µM DHE for 10 minutes at 37 °C. Cells were then 192 immediately imaged using a FV10i LIV Laser Scanning Confocal Microscope (Olympus Canada 193 Inc, ON). Controls were used to correct for autofluorescence. After entering the cell, DHE is 194 oxidized by ROS, mainly superoxide, to red fluorescent products that accumulate in the nucleus 195 (27) . 196
197
F/G actin assay 198
Freshly isolated cardiomyocytes were plated on laminin-coated culture dishes. Cells were treated 199 with C3 exoenzyme (2 µg/mL) or cytochalasin D (1,2 or 5 µM) for 24 hours or left untreated. 200
Myocytes were then processed for the isolation and determination of globular actin (G-actin) and 201 filamentous actin (F-actin) content using a commercially available assay kit (Cytoskeleton Inc, 202 CO) . 203
204
Statistical analysis 205
All values are expressed as means ± SEM; n denotes the number of animals in each group. 206
Statistical analysis of all data was performed using one-way ANOVA followed by the Newman-207 Keuls test when more than two groups were compared, using GraphPad Prism version 5.00 for 208
Windows (GraphPad Software, San Diego, CA, USA). 209
210
Results
212
High glucose increases RhoA/ROCK pathway activity in isolated cardiomyocytes 213
We first investigated whether the increased activation of the RhoA/ROCK pathway that we 214 previously detected in hearts of diabetic rats (32) could be attributed to exposure of 215 cardiomyocytes to high glucose. Incubation of adult cardiomyocytes isolated from non-diabetic 216 rat hearts in 25 mM glucose produced a time dependent increase in ROCK activity that reached 217 statistical significance after 12 hours or more of incubation ( figure 1A ). To further confirm the 218 effect of high glucose on ROCK activity, we determined the level of Thr We next determined whether the RhoA/ROCK pathway regulated PKCβ 2 activity under high 229 glucose conditions. In agreement with our previous results (38), incubation in high glucose had 230 no significant effect on total PKCβ 2 levels but increased its Thr641 phosphorylation. The latter 231 was significantly attenuated by inhibition of ROCK with Y27632 or H-1152 ( figure 2B ). 232
Phosphorylation of Thr641 is essential for the appropriate subcellular localization and catalytic 233 function of PKCβ 2 (16, 28) and is used as an index of PKCβ 2 activation (1, 9, 35, 45) . Toconfirm involvement of the pathway, cardiomyocytes were also treated with the Rho inhibitor C3 235 transferase at a concentration (2 µg/mL) that effectively inhibited ROCK activity (figure 2A), 236 which significantly decreased PKCβ 2 phosphorylation (figure 2B). Lastly, cardiomyocytes were 237 infected with Ad-RhoA N19 and incubated in high or low glucose for 24 hours. In preliminary 238 experiments using Ad-GFP, we found that the cardiomyocyte transduction efficiency was 85% 239 after 24 hours (data not shown). Ad-RhoA N19 treatment completely prevented the high glucose-240 induced increase in RhoA activity (figure 2C), and this was associated with loss of the high 241 glucose-induced increase in PKCβ 2 Thr641 phosphorylation ( figure 2D ). 242
243
RhoA/ROCK inhibition attenuates PKCβ 2 Thr641 phosphorylation in cardiomyocytes isolated 244 from diabetic rat hearts 245
We next investigated whether RhoA/ROCK regulated PKCβ 2 activity in vivo in hearts of diabetic 246 rats. Cardiomyocytes isolated from diabetic and control rat hearts were treated with C3 247 transferase or Y27632 for 8 hours (longer periods of incubation caused rapid decline in the 248 viability of cardiomyocytes from diabetic rat hearts). It is noteworthy that ROCK activity in 249 cardiomyocytes isolated from diabetic rat hearts remained significantly elevated for up to 16 250 hours after isolation ( figure 3A ). The diabetes-induced elevation of PKCβ 2 Thr641 251 phosphorylation was attenuated to control levels by both Y27632 and by C3 transferase (figure 252 3B), which had no effect on PKCβ 2 phosphorylation in control cardiomyocytes (data not shown). 253
The inhibitory effect of Y27632 on PKCβ 2 Thr641 phosphorylation in diabetic cardiomyocytes 254 was evident even after short-term (30 minutes) treatment (figure 3C). 255
We also determined the effect of C3 transferase and Y27632 treatment on translocation of 256 PKCβ 2 to the plasma membrane, a hallmark of PKC activation (16). There was a marked increasein the level of PKCβ 2 in the membrane fraction in diabetic cardiomyocytes that was normalized 258 by C3 transferase and Y27632 as well as by the selective PKCβ 2 translocation inhibitor peptide 259 (Tat-β 2 V5), which also normalized PKCβ 2 Thr641 phosphorylation in cardiomyocytes from 260 diabetic rats (figure 3D). These inhibitors had no effect on PKCβ 2 translocation in control 261 cardiomyocytes ( figure 3F ). 262
263
ROCK inhibition attenuates the PKCβ 2 mediated iNOS induction in cardiomyocytes isolated 264 from diabetic rat hearts 265
The RhoA/ROCK pathway regulation of PKCβ 2 activation would also be expected to affect the 266 expression of its downstream target, iNOS. Indeed, treatment with either Y27632 or the PKCβ 267 inhibitor LY333531, at a concentration that we have previously shown to be effective in 268 inhibiting PKCβ 2 activity (38) and that is selective for PKCβ (26), significantly reduced the 269 diabetes-induced upregulation of iNOS (figure 4A). Additionally, Tat-β 2 V5 also significantly 270 attenuated increased iNOS expression in cardiomyocytes from diabetic rat hearts (figure 4B). On 271 the other hand, C3 transferase failed to significantly alter iNOS expression in diabetic 272 cardiomyocytes, although there was a slight downward trend (figure 4A). For this reason and 273 since C3 inhibits not only RhoA, but also RhoB and C, we determined the effect of Ad-RhoA 274 N19 on iNOS expression in cardiomyocytes incubated in high glucose for 24 hours. Ad-RhoA 275 N19 treatment abolished the high glucose-induced increase in iNOS expression ( figure 4C ). 276
Interestingly, Ad-RhoA N19 significantly increased iNOS expression in cardiomyocytes 277 incubated in low glucose (figure 4C). We did not infect diabetic cardiomyocytes with Ad-RhoA 278 N19 since it was not possible to maintain the cells viable for a time period sufficient for loss of 279
RhoA activity.
Inhibition of PKCβ 2 , iNOS, RhoA or ROCK disrupts the positive feedback loop and abrogates 281 the sustained RhoA/ROCK pathway activation in diabetes 282
We next tested whether the hypothesized feed forward loop could be detected in diabetic 283 cardiomyocytes. We found that the diabetes-induced increase in ROCK activity was not only 284 blocked by Y27632 and C3 transferase, but also by treatment with the iNOS inhibitor 1400W for 285 8 hours ( figure 5A ). The latter also normalized PKCβ 2 phosphorylation and translocation (figures 286 3B and E), consistent with the proposed feedback loop. ROCK activity was also markedly 287 attenuated by LY333531 ( figure 5A ) and Tat-β 2 V5 treatment for 8 hours in diabetic 288 cardiomyocytes (figure 5B). In contrast, treatment with Tat-β 2 V5 for 30 minutes did not 289 significantly alter ROCK activity (figure 5C). 290
In order to establish that ROCK positively reinforces RhoA through the PKCβ 2 /iNOS pathway, 291
we determined the effect of the abovementioned inhibitors on RhoA expression and inhibitory 292 Ser188 phosphorylation. In vehicle-treated cardiomyocytes from diabetic rats, RhoA expression 293 but not Ser188 phosphorylation was significantly increased (figure 6A). The resulting diminished 294 p-RhoA/RhoA ratio leads to a larger pool of readily activatable RhoA, which contributes to the 295 elevated ROCK activity in the diabetic state. Treatment with Y27632, 1400W or LY333531 296 failed to significantly alter RhoA ser188 phosphorylation (figure 6A). On the other hand, these 297 treatments were able to significantly decrease RhoA expression (figure 6A) normalizing the p-298
RhoA/RhoA ratio (figure 6B). The same treatments had no effect on RhoA in control 299 cardiomyocytes (data not shown). Additionally, Tat-β 2 V5 significantly reduced RhoA expression 300 in cardiomyocytes from diabetic animals compared to cardiomyocytes treated with Tat Oxidative stress plays an important role in mediating the deleterious effects of PKCβ 2 in 319 diabetes. Therefore, we determined the effect of disruption of the loop on diabetes-induced 320 oxidative stress. Incubation of cardiomyocytes from diabetic rats with C3 or Y26732 for one 321 hour produced a significantly greater reduction in ROS production than did either Tat-β 2 V5 or 322 1400W ( figure 8B ). However, following 8 hours incubation, all inhibitors markedly attenuated 323 ROS to near control levels ( figure 8D) . 324 325 Discussion 327
The RhoA/ROCK pathway has been shown by numerous researchers to play a pivotal role in 328 cardiovascular pathologies and there is great interest in ROCK inhibitors as potential therapies 329 for many of these diseases [reviewed in (15)]. We reported previously that the activity of the 330
RhoA/ROCK pathway is elevated in diabetic cardiomyopathy and that acute treatment with 331 ROCK inhibitors significantly improves the contractile function of hearts from diabetic rats (32). 332
The novel findings of the present study are that in the diabetic heart, 1) activation of the 333 RhoA/ROCK pathway leads to increased PKCβ 2 activity; 2) the increased activity of PKCβ 2 and 334 the RhoA/ROCK pathway are sustained by a positive feedback loop; and 3) disrupting the loop 335 markedly attenuates diabetes-induced increases in oxidative stress. These data suggest that the 336 mechanism by which the RhoA/ROCK pathway contributes to contractile dysfunction in the 337 diabetic heart is at least in part through activation of PKCβ 2 and promotion of the production of 338
ROS. 339
There is much evidence to suggest that hyperglycemia-induced activation of PKCβ 2 in the heart 340 contributes to the development of diabetic cardiomyopathy (22, 47, 56) . The results of the 341 present study show that treatment of cardiomyocytes incubated in high glucose or isolated from 342 diabetic rat hearts with a concentration of Y27632 that has been shown to be selective for ROCK 343 over other kinases including PKC (13), as well as inhibition of ROCK activation with either C3 344 exoenzyme or by overexpression of Ad-RhoA N19, prevented the increase in PKCβ 2 activity. 345
These data strongly implicate the RhoA/ROCK pathway in the activation of PKCβ 2 in the 346 diabetic heart. Our further observation that inhibition of ROCK or PKCβ 2 prevented the diabetes-347 induced increase in RhoA expression supports the hypothesis that the interaction between the 348 RhoA/ROCK pathway and PKCβ 2 is in the form of a positive feedback loop. The finding thatinhibition of iNOS, which we have shown previously to prevent the diabetes-induced increase in 350
RhoA expression and ROCK activity, also prevented the activation of PKCβ 2 in the heart 351 provides additional evidence in support of the loop. This could not be detected in 352 cardiomyocytes isolated from control hearts, indicating that this feedback mechanism occurs 353 only under pathophysiological conditions. 354
There is compelling evidence linking increased oxidative stress, in particular ROS production, to 355 the development of diabetic cardiovascular complications (6, 39). As noted in the introduction, 356 oxidative stress contributes to the activation of PKCβ 2 in the heart as in other tissues (19, 57), 357 while increased PKCβ 2 activity has been shown to lead to increased production of ROS in 358 diabetes (30, 34, 40, 42, 44, 63) . Similarly, oxidative stress appears to positively regulate 359 induction of iNOS (61), while uncoupling of both eNOS and iNOS in diabetes leads to the 360 generation of ROS (43, 49). Consistent with this, direct inhibition of both PKCβ 2 and iNOS 361 decreased ROS production in diabetic cardiomyocytes in the present study. In addition, however, 362 we found that inhibition of both RhoA and ROCK also markedly attenuated ROS production. 363 ROS production was reduced to the same extent by long-term incubation with each of the 364 inhibitors, a finding that is consistent with the presence of the loop and that demonstrates that its 365 disruption at any point reduces oxidative stress. It should also be noted that short-term exposure 366 to inhibitors of the RhoA/ROCK pathway produced more profound decreases in ROS production 367 than did direct inhibition of PKCβ 2 or iNOS. This may indicate that in addition to increasing 368 oxidative stress by promoting the activity of the loop, RhoA/ROCK may promote production of 369 ROS through other mechanisms. 370
The production of ROS has been implicated in the phenomenon known as 'metabolic memory', 371 the persistence of diabetic complications despite normalization of glucose levels (7, 21).
Interestingly, we found that ROS production remained elevated for at least 8 hours after 373 cardiomyocytes isolated from diabetic hearts were cultured in low glucose, and this was 374 associated with continued activation of ROCK and PKCβ 2 . Although it is not clear how long this 375 sustained activation continues, the possible role of the positive feedback loop in metabolic 376 memory in diabetic hearts warrants further investigation. 377
The results of the present study suggest that an intact actin cytoskeleton is required to sustain the 378 activity of the positive feedback loop and its production of ROS. The RhoA/ROCK pathway is a 379 well-known regulator of the actin cytoskeleton (8, 54), and we have shown previously that actin 380 polymerization is increased in cardiomyocytes from diabetic rats as a result of RhoA/ROCK 381 activation (32). On the other hand, an intact cytoskeleton was shown to be required for In conclusion, the results of this study suggest that, in the diabetic heart, the RhoA/ROCK 432 pathway contributes to contractile dysfunction at least in part by sustaining PKCβ 2 activation, 433 iNOS induction and ROS production via a positive feedback loop that requires an intact 434 cytoskeleton. The significance of this loop is that it links proteins that have been shown to play a 435 pivotal role in the pathogenesis of diabetic cardiomyopathy since inhibition of ROCK, PKCβ 2 or 436 iNOS has been shown by us or others to substantially improve cardiac function in the diabetic 437 state (11, 32, 52, 62 
